))
Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)
Manage episode 297177464 series 2907690
内容由Jody Vance提供。所有播客内容（包括剧集、图形和播客描述）均由 Jody Vance 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Deborah Rathjen, CEO of Bioasis Technologies (BTI.V) talks about the company's ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer's disease, Lewy Body Dementia and Parkinson's. In short, Bioasis' final frontier solution could very well revolutionize medical science, potentially helping to heal the one billion people suffering from neurological disorders worldwide. Tune in!
55集单集
分享
